

## FORM 5

### QUARTERLY LISTING STATEMENT

Name of Listed Issuer: LeenLife Pharma International Inc. (the "Issuer").

Trading Symbol: LLP

This Quarterly Listing Statement must be posted on or before the day on which the Issuer's unaudited interim financial statements are to be filed under the *Securities Act*, or, if no interim statements are required to be filed for the quarter, within 60 days of the end of the Issuer's first, second and third fiscal quarters. This statement is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by the Exchange Policies. If material information became known and was reported during the preceding quarter to which this statement relates, management is encouraged to also make reference in this statement to the material information, the news release date and the posting date on the Exchange website.

#### **General Instructions**

- (a) Prepare this Quarterly Listing Statement using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the following items must be in narrative form. When the answer to any item is negative or not applicable to the Issuer, state it in a sentence. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Listed Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

There are three schedules which must be attached to this report as follows:

#### **SCHEDULE A: FINANCIAL STATEMENTS**

Financial statements are required as follows:

Financial statements for the three months ended June 30, 2017

#### **SCHEDULE B: SUPPLEMENTARY INFORMATION**

The supplementary information set out below must be provided when not included in Schedule A.

## **1. Related party transactions**

During the period ended June 30, 2017, the Company entered into the following transactions with related parties:

- (a) Management fees of \$55,500 were paid or accrued to be paid to Stan Lis, CEO and a director of the Company;
- (b) Automobile expenses of \$4,500 were paid or accrued to be paid to Stan Lis, CEO and a director of the Company;
- (c) Professional fees of \$55,500 were paid or accrued to be paid to Casey Forward, CFO and a director of the Company;
- (d) Automobile expenses of \$4,500 were paid or accrued to be paid to Casey Forward, CFO and a director of the Company;
- (e) Stock based compensation to directors and officers was estimated at \$184,561.

During the period ended June 30, 2016 the following transactions were entered into:

- (f) Management fees of \$54,000 were paid or accrued to be paid to Stan Lis, CEO and a director of the Company;
- (g) Consulting fees of \$54,000 were paid or accrued to be paid to Casey Forward, CFO and a director of the Company;

All related party transactions are in the normal course of operations and have been measured at the agreed to amounts, which is the amount of consideration established and agreed to by the related parties. As at June 30, 2017, \$50,033 (March 31, 2017, \$64,303) was owing to related parties.

## **2. Summary of securities issued and options granted during the period.**

- (a) summary of securities issued during the period,

Date of Issue	Type of Security (common shares, convertible debentures, etc.)	Type of Issue (private placement, public offering, exercise of warrants, etc.)	Number	Price	Total Proceeds	Type of Consideration (cash, property, etc.)	Describe relationship of Person with Issuer (indicate if Related Person)	Commission Paid
	Nil							

(b) summary of options granted during the period,

Date	Number	Name of Optionee if Related Person and relationship	Generic description of other Optionees	Exercise Price	Expiry Date	Market Price on date of Grant
2017-06-21	600,000	Stan Lis, CEO		\$0.18	June 20/20	\$0.15
2017-06-21	600,000	Casey Forward, CFO		\$0.18	June 20/20	\$0.15
2017-06-21	750,000	Mike Wystach, Director		\$0.18	June 20/20	\$0.15
2017-06-21	100,000	Glen Macdonald, Director		\$0.18	June 20/20	\$0.15
2017-06-21	100,000	Marcin Lukaszewicz, Director		\$0.18	June 20/20	\$0.15
2017-06-21	1,250,000		Consultants	\$0.18	June 20/20	\$0.15

### 3. Summary of securities as at the end of the reporting period.

(a) Included in financial statements

### 4. List the names of the directors and officers, with an indication of the position(s) held, as at the date this report is signed and filed.

#### OFFICERS AND DIRECTORS

Stan Lis	President, CEO & Director
Casey Forward	Director & CFO
Marcin Lukaszewicz	Director

Mike Wystrach  
Brian Banducci  
Glen Macdonald

Director  
Director  
Director

## SCHEDULE C: MANAGEMENT DISCUSSION AND ANALYSIS

Interim MD&A attached.

### Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Quarterly Listing Statement.
2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 5 Quarterly Listing Statement is true.

Dated August 28, 2017.

Casey Forward  
Name of Director or Senior Officer

  
Signature

CFO  
Official Capacity

<b>Issuer Details</b>		
Name of Issuer	For Quarter Ended	Date of Report YY/MM/D
LeenLife Pharma International Inc.	June 30, 2017	17/08/28
Issuer Address		
380 – 580 Hornby Street		
City/Province/Postal Code	Issuer Fax No. ( )	Issuer Telephone No. (778) 688-1799
Vancouver, BC, V6C 3G6		
Contact Name	Contact Position	Contact Telephone No.
Casey Forward	CFO	778 688-1799
Contact Email Address	Web Site Address	
casey@caseyforward.com	<a href="http://www.LeenLifePharma.com">http://www.LeenLifePharma.com</a>	